{
    "nctId": "NCT01094184",
    "briefTitle": "A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer",
    "officialTitle": "Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Patients With Advanced Triple Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Score at Cycle 2",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed triple-negative (estrogen, progesterone, and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease\n* Participant who in the Investigator's opinion requires combination therapy for their disease\n* Life expectancy of greater than or equal to (\\>/=)12 weeks\n\nExclusion Criteria:\n\n* Previous chemotherapy for metastatic breast cancer\n* Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain)\n* Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}